指南与共识消化、代谢与肾脏急症

日本糖尿病患者治疗相关严重低血糖的现状:日本糖尿病学会严重低血糖调查委员会报告

The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society.
指南 / 共识 · Diabetol Int · 2018-03-02
一句话结论日本糖尿病学会调查显示,严重低血糖住院患者中2型糖尿病占多数且年龄更大、肾功能更差、HbA1c更低,需优化降糖治疗并加强低血糖教育。

日本糖尿病学会于2014年4月1日至2015年3月31日开展严重低血糖调查,收集193家机构信息及113家机构的798例病例报告。严重低血糖定义为需要他人协助治疗的低血糖症状,且发生时或就诊时静脉血浆葡萄糖明确低于60 mg/dL(毛细血管全血葡萄糖低于50 mg/dL)。2型糖尿病患者年龄中位数77.0岁,显著高于1型糖尿病患者的54.0岁(P<0.001),eGFR中位数50.6 mL/min/1.73 m2显著低于1型糖尿病患者的73.3 mL/min/1.73 m2(P<0.001)。2型糖尿病患者严重低血糖发生时HbA1c中位数6.8%显著低于1型糖尿病患者的7.5%(P<0.001)。调查首次揭示日本治疗相关严重低血糖现状,强调需通过低血糖教育和优化降糖治疗实施预防措施。

要点

  • 严重低血糖定义:需要他人协助治疗的低血糖症状,且发生时或就诊时静脉血浆葡萄糖明确低于60 mg/dL(毛细血管全血葡萄糖低于50 mg/dL)。
  • 798例严重低血糖报告中,2型糖尿病480例,年龄中位数77.0岁,显著高于1型糖尿病患者的54.0岁(P<0.001)。
  • 2型糖尿病eGFR中位数50.6 mL/min/1.73 m2,显著低于1型糖尿病患者的73.3 mL/min/1.73 m2(P<0.001)。
  • 2型糖尿病严重低血糖发生时HbA1c中位数6.8%,显著低于1型糖尿病患者的7.5%(P<0.001)。
  • 2型糖尿病降糖方案:胰岛素制剂292例(60.8%,其中29例联用磺脲类),磺脲类159例(33.1%,未用胰岛素),未用胰岛素或磺脲类29例(6.0%)。

适用人群与场景

  • 日本糖尿病学会认证的糖尿病教育机构就诊的糖尿病患者,调查期间发生严重低血糖者。
  • 病例报告包括1型糖尿病240例、2型糖尿病480例、其他类型糖尿病78例。

诊断标准与关键阈值

  • 严重低血糖定义:存在需要他人协助治疗的低血糖症状,且发生时或诊断时或就诊时静脉血浆葡萄糖明确低于60 mg/dL(毛细血管全血葡萄糖低于50 mg/dL)。

研究设计与关键结果

  • 调查为日本糖尿病学会发起的严重低血糖现状调查,收集193家机构信息,113家机构提交798例病例报告。
  • 193家应答机构中149家设有急诊科,每年需急诊转运至这些机构的患者中位数4962例,其中严重低血糖占0.34%。
  • 应答机构每年收治严重低血糖患者2237例,每中心6.5例;其中1171例住院,每中心4.0例,占每年严重低血糖就诊患者的52.3%。
  • 2型糖尿病年龄中位数77.0(68.0-83.0)岁显著高于1型糖尿病54.0(41.0-67.0)岁(P<0.001);BMI 22.0(19.5-24.8)kg/m2显著高于1型糖尿病21.3(18.9-24.0)kg/m2(P=0.003)。
  • 2型糖尿病eGFR中位数50.6(31.8-71.1)mL/min/1.73 m2显著低于1型糖尿病73.3(53.5-91.1)mL/min/1.73 m2(P<0.001)。
  • 严重低血糖发生时HbA1c中位数:全部患者7.0(6.3-8.1)%,1型糖尿病7.5(6.9-8.6)%,2型糖尿病6.8(6.1-7.6)%,2型糖尿病显著低于1型糖尿病(P<0.001)。
  • 严重低血糖前驱症状:全部患者中有症状35.5%、无症状35.6%、不详28.9%;1型糖尿病有症状比例41.0%显著低于2型糖尿病56.9%。
  • 798例患者中296例(37.2%)既往曾因严重低血糖需要急诊转运。

证据类型、等级与局限

  • 证据类型:日本糖尿病学会调查委员会开展的严重低血糖现状调查(基于网络的匿名病例登记)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 调查结果提示,2型糖尿病患者发生严重低血糖时年龄更大、肾功能更差、HbA1c更低,需优化降糖治疗并加强低血糖教育以实施预防措施。

指南或共识出处

  • 日本糖尿病学会(Japan Diabetes Society)严重低血糖调查委员会报告,发表于Diabetol Int。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Despite great strides in pharmacotherapy for diabetes, there is increasing concern over the risk of hypoglycemia in patients with diabetes receiving pharmacotherapy as they become increasingly older. This has prompted the Japan Diabetes Society (JDS) to initiate a survey on the current status of severe hypoglycemia in clinical settings. In July 2015, following approval from the JDS Scientific Survey/Research Ethics Committee, the JDS extended an invitation to executive educators, who represented a total of 631 health-care facilities accredited by the JDS for diabetes education, to participate in the proposed survey. Of these, those who expressed their willingness to participate in the survey were sent an application form required for obtaining ethical approval at these health-care facilities and were then asked, following approval, to enter relevant clinical data on an unlinked, anonymous basis in a Web-based registry. The current survey was fully funded by the JDS Scientific Survey/Research Committee. A case registry (clinical case database) was launched after facility-specific information (healthcare facility database) was collected from all participating facilities and after informed consent was obtained from all participating patients. With severe hypoglycemia defined as the "presence of hypoglycemic symptoms requiring assistance from another person to treat and preferably venous plasma glucose levels at onset/diagnosis of disease or at presentation clearly less than 60 mg/dL (capillary whole blood glucose, less than 50 mg/dL)", the current survey was conducted between April 1, 2014 and March 31, 2015, during which facility-specific information was collected from a total of 193 facilities with a total of 798 case reports collected from 113 facilities. Of the 193 respondent facilities, 149 reported having an emergency department as well, with the median number of patients who required emergency transportation services to reach these facilities totaling 4962 annually, of which those with severe hypoglycemia accounted for 0.34% (17). The respondent facilities accommodated a total of 2237 patients with severe hypoglycemia annually, with the number of patients thus accommodated being 6.5 patients per site. A total of 1171 patients were admitted for severe hypoglycemia, with the number of patients thus admitted being 4.0 per site, who accounted for 52.3% of all patients visiting annually for severe hypoglycemia. A review of the 798 case reports collected during the survey revealed that 240, 480, and 78 patients had type 1 diabetes, type 2 diabetes, and other types of diabetes, respectively; those with type 2 diabetes were shown to be significantly older [median (interquartile range), 77.0 (68.0-83.0)] than those with type 1 diabetes [54.0 (41.0-67.0)] (P < 0.001); and the BMI was shown to be significantly higher for those with type 2 diabetes [22.0 (19.5-24.8) kg/m2] than for those with type 1 diabetes [21.3 (18.9-24.0) kg/m2] (P = 0.003). It was also found that the median estimated glomerular filtration rate (eGFR) was significantly lower among those with type 2 diabetes [50.6 mL (31.8-71.1)/min/1.73 m2] than among those with type 1 diabetes [73.3 (53.5-91.1) mL/min/1.73 m2] (P < 0.001). Again, the median HbA1c value at onset of severe hypoglycemia was shown to be 7.0 (6.3-8.1)% among all patients examined, 7.5 (6.9-8.6)% among those with type 1 diabetes, and 6.8 (6.1-7.6)% among those with type 2 diabetes, with the HbA1c value at onset of hypoglycemia being significantly lower among those with type 2 diabetes (P < 0.001). Antecedent symptoms of severe hypoglycemia were shown to be present, absent, and unknown in 35.5, 35.6, and 28.9% of all patients, respectively, with the incidence of symptomatic hypoglycemia being significantly lower among those with type 1 diabetes (41.0%) than among those with type 2 diabetes (56.9%). The antidiabetic agents used in those with type 2 diabetes were insulin preparations (292 patients including 29 receiving concomitant sulfonylureas [SUs]) (60.8%), SUs (159 insulin-naïve patients) (33.1%), and no insulin preparations or SUs (29 patients) (6.0%). Of the 798 patients surveyed, 296 patients (37.2%) were shown to have required emergency transportation services for severe hypoglycemia before. Thus, the survey revealed, for the first time, the current status of treatment-related severe hypoglycemia in Japan and clearly highlights the acute need for implementing preventive measures against hypoglycemia, not only through education on hypoglycemia but also through optimization of antidiabetic therapy for those at high risk of severe hypoglycemia or those with a history of severe hypoglycemia.

来源:Diabetol Int,查看原文。版权归原作者所有。

参考来源

  1. Namba M, Iwakura T, Nishimura R, et al. The current status of treatment-related severe hypoglycemia in Japanese patients with diabetes mellitus: a report from the committee on a survey of severe hypoglycemia in the Japan Diabetes Society. Diabetol Int. 2018. PMID: 30603355. doi:10.1007/s13340-018-0346-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。